Morgan Stanley has recently initiated Recursion Pharmaceuticals Inc (RXRX) stock rating, as announced on May 22, 2023, according to Finviz. Earlier, on March 16, 2023, Needham had initiated the stock ...

On Thursday, Immunic Inc (IMUX) stock saw a modest uptick, ending the day at $1.59 which represents a slight increase of $0.05 or 3.25% from the prior close of $1.54. The stock opened at $1.54 and ...

Analysts at SVB Leerink said that while the offer is fair at that price, Alexion is a “scarce and high-quality asset,” which could prompt an offer from another company. In the past ...

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, ...

Analysts at SVB Leerink rounded up the five best and the five worst acquisitions of the last decade. The list of best and worst deals are based on an analysis of all the transactions over the last ...

Leerink Partners downgraded while Truist defended Regeneron (NASDAQ:REGN) after a judge denied the company’s motion for a preliminary injunction against Amgen (NASDAQ:AMGN) biosimilar for its ...

Leerink assumed coverage of Mind Medicine with an Outperform rating and $20 price target The firm likes the emerging psychedelics space with increasing investment in clinical development across ...

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, ...

Recent stories: How SVB Leerink is luring top bankers with juicy pay and a big opportunity to build a new dealmaking powerhouse Goldman Sachs is raising salaries for 2nd-year analysts to $125K and ...

ICON Public Limited (NASDAQ:ICLR) traded higher on Wednesday after Leerink Partners launched its coverage with a buy-equivalent Outperform recommendation, citing a business model centered on large ...

Chazen Institute for Global Business. I identify at least six red flags about building risk in SVB since 2021 in their public financial statements. SVB was functionally bankrupt by July 31 ...